Hydroxyethyl Starch Derivatives clinical trials
Also written Hydroxyethyl starch, Volulyte and HES 130/0.4.
A group of medicines. HES 130-0.4 (16 studies) is counted on its own page; this page counts the studies that name Hydroxyethyl Starch Derivatives itself.
How each study uses Hydroxyethyl Starch Derivatives is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Hydroxyethyl Starch Derivatives studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Medicines filed under Hydroxyethyl Starch Derivatives
As reviewed, so not every one. Each counts its studies on its own page, not here.
Studies by the year they started
45 studies that test it; most in 2009 (7)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 2 |
| 2009 | 7 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 5 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 6 |
| 2017 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2023 | 1 |
| 2024 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 39
Konkuk University Medical Center (6) · Fresenius Kabi (5) · The Cleveland Clinic (2) · General Hospital of Ningxia Medical University (2) · Seoul National University Hospital (2) · Tanta University (1) · Queen Fabiola Children's University Hospital (1) · Indiana University (1)
Often tested with
Tested in the same studies.
Albumins human (2) · Sodium Chloride (2) · Ringer's Lactate (2) · Hydrocortisone (1) · Crystalloid Solutions (1) · SIC-8000 (1) · Whole blood (1) · Bupivacaine (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Hydroxyethyl Starch Derivatives.
- Dec 2026Crystalloid vs Colloid for Hemodynamics During Anesthesia Induction in TAVR PatientsNot applicable · Air Force Military Medical University, China
Studies
Open first, then newest update. How each study uses Hydroxyethyl Starch Derivatives is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 46
- Hydroxyethyl Starch Versus Crystalloid and Postoperative Major Adverse Kidney ComplicationsRecruitingPhase 4Seoul National University HospitalNCT07410988Written as Volulyte® (6% HES 130/0.4 in balanced solution)
- Crystalloid vs Colloid for Hemodynamics During Anesthesia Induction in TAVR PatientsNot yet recruitingNot applicableAir Force Military Medical University, ChinaNCT07329660Written as Hydroxyethyl starch 130/0.4
- Mild ANH on Pre-bypass Coagulation Function During Cardiac SurgeryNot yet recruitingNot applicableKonkuk University Medical CenterNCT06664320Written as hydroxyethyl starch (HES 130/0.6)
- Safety and Efficacy of Perioperative Volume Replacement with Volulyte 6% in Moderate-to-high Cardiovascular Risk Patients Having Major Abdominal SurgeryNot yet recruitingPhase 4Xiangya Hospital of Central South UniversityNCT06663254Written as Hydroxyethyl starch 130/0.4
- 6% Hydroxyethyl Starch (130/0.4) Coload for Postspinal Anesthesia HypotensionRecruitingNot applicableGeneral Hospital of Ningxia Medical UniversityNCT05475886Written as Hydroxyethyl starch 130/0.4
- Impact of Intravascular Fluid Resuscitation and Whole Blood ViscosityCompletedNot applicableKonkuk University Medical CenterNCT02700607Written as Intravenous HES
- The Potential Therapeutic Role of Hydroxyethyl Starch and Hydrocortisone in Acute Aluminum Phosphide PoisoningCompletedNot applicableTanta UniversityNCT04465539Written as Hydroxyethyl Starch 130-0.4 60 MG/ML [Voluven]
- Endothelial Function After Cardiac SurgeryCompletedNot applicableThe Cleveland ClinicNCT02882074Written as Hydroxyethyl starch
- Safety and Efficacy of 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Patients Undergoing Elective Abdominal SurgeryCompletedPhase 4Fresenius KabiNCT03278548Written as Volulyte 6%
- Comparison of Hydroxyethyl Starch and Crystalloid Coload Combined With Norepinephrine Infusion for HypotensionCompletedNot applicableGeneral Hospital of Ningxia Medical UniversityNCT05475990Written as Hydroxyethyl starch
- Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical PatientsCompletedPhase 3The Cleveland ClinicNCT02192502Written as HES 130/0.4 (Voluven)
- Safety and Efficacy of a 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Trauma PatientsCompletedPhase 4Fresenius KabiNCT03338218Written as Volulyte 6%
- Colloids in Pediatric Cardiac Surgery: Comparison Between a Balanced and a Non-balanced ColloidCompletedPhase 3Queen Fabiola Children's University HospitalNCT02584868Written as Hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution
- Acute Normovolemic Hemodilution on ROTEM in Cardiac SurgeryCompletedNot applicableKonkuk University Medical CenterNCT02502448Written as hydroxyethyl starch (HES 130/0.6)
- Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity for Colon SurgeryStatus unknownNot applicableKonkuk University Medical CenterNCT02770027Written as Intravenous HES
- A Comparison of Eleview Versus Hetastarch as Injectate for EMRCompletedPhase 4Indiana UniversityNCT03350217Written as Hetastarch
- HES Patch Versus Blood PatchCompletedNot applicableUniversity Hospital, Strasbourg, FranceNCT02570724Written as injection of HES " Voluven® "
- Starch or Saline After Cardiac SurgeryTerminatedNot applicableLondon Health Sciences CentreNCT00964015Written as 6% Hydroxyethyl Starch 130/0.4
- Hemostasis Evolution During Fluid Loading in Abdominal Surgery. Effects of Fluid Choice: Saline Versus Hydroxyethyl Starch (HAEMO Study)CompletedPhase 4University Hospital, Clermont-FerrandNCT03420261Written as HES 130/0.4
- Crystalloids or Colloids for Goal-directed Fluid Therapy With Closed-loop Assistance in Major SurgeryCompletedPhase 4Brugmann University HospitalNCT02312999Written as Volulyte
See all 46 studies that test Hydroxyethyl Starch Derivatives →
Given beside what is tested · 1 — Hydroxyethyl Starch Derivatives is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with Hydroxyethyl Starch Derivatives
Codes
What other systems call Hydroxyethyl Starch Derivatives · ClinicalTrials.gg INT007633
- MeSH (NLM) D006895Hydroxyethyl Starch DerivativesConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 1GVO236S58HYDROXYETHYL STARCH 130/0.4Confirmed FDA, NLM
- RxNorm 1363352One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D006895 | Hydroxyethyl Starch Derivatives | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 1GVO236S58 | HYDROXYETHYL STARCH 130/0.4 | Confirmed FDA, NLM |
| RxNorm | 1363352 | — | One source FDA |
Also registered as hetastarch (UNII 875Y4127EA · RxNorm 5531) and pentastarch (UNII MOQ3RNM0SV · RxNorm 816249).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.